+116.7%
MPC vs MRNA
+755.5%
-638.8%
-23.1%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 1y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | +0.4% | -3.4% | +3.9% | +0.4% |
| 7D | +11.2% | -12.1% | +23.4% | +11.1% |
| 30D | -14.5% | -1.3% | -13.2% | -14.4% |
| 3M | +16.7% | +250.9% | -234.3% | +19.4% |
| 6M | +67.6% | +343.0% | -275.5% | +71.6% |
| YTD | +157.9% | +657.4% | -499.5% | +157.1% |
| 1Y | +116.7% | +794.9% | -678.3% | +108.9% |
| All | +116.7% | +755.5% | -638.8% | +108.9% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 1y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
1y analysis · Full analysis span regression · 6 months rolling